LeMaitre Vascular (NSDQ:LMAT) posted fourth-quarter results that beat the overall consensus forecast on Wall Street.
The Burlington, Massachusetts-based company yesterday evening reported profits of $6.2 million, or 28¢ per share, on sales of $39.5 million for the three months ended Dec. 31, 2021, for a bottom-line loss of -12.2% on sales growth of 5.21% compared with Q4 2020.
Earnings per share were 28¢, 3¢ ahead of The Street, where analysts were looking for sales of $39.7 million.
LeMaitre Vascular expects Q1 2022 sales to be in the range of $37.7 million and $39.7 million with an EPS range of 26¢ to 30¢. Full-year revenue is expected to be in the range of $162 million to $166 million with an EPS range estimate of $1.35 to $1.45.
Shares in LMAT were down slightly at $45.65 apiece in morning trading today.
MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up 1%.
